Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05825404 · ClinicalTrials.gov registry record · NA
Smart Lighting for Nursing Home Residents With Dementia
A NA study of Alzheimer's Disease and Related Dementias, sponsored by Penn State University.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT05825404 is a NA study of Alzheimer's Disease and Related Dementias that has completed, run by Penn State University. The registered enrollment target is 51 participants, below the 1,629-participant average among 5 other Alzheimer's Disease and Related Dementias trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05825404, a NA study of Alzheimer's Disease and Related Dementias, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight. This SABL includes tunable LED lights, photosensors, and controllers. The SABL system has a pre-programmed 24-hour control schedule for illuminance settings to mimic the natural bright-dark cycle. It will automatically adjust the lights to accommodate the daylight effect to minimize staff burden and maximize the LI effect. The SABL will be installed in participants' bedrooms and designated areas in the dining rooms and activity rooms for four weeks. Each participant will wear a personal light monitor to measure the lighting dosage each participant receives. This study will address three aims: 1) pilot test the effect of SABL on reducing agitation in persons with ADRD, 2) evaluate the fidelity of the SABL delivery, and 3) evaluate the feasibility of implementing the SABL. The study will be conducted in two NHs in Pennsylvania. For aims 1 and 2, the investigators will use a crossover, cluster randomized control trial (RCT) and will enroll residents with ADRD and agitation. For aim 3, the investigators will use a mixed methods design and will interview NH stakeholders to evaluate the acceptability, feasibility, and appropriateness of the intervention. This is the first study that incorporates daylight in ambient light interventions and the first study that addresses the measurement, feasibility, and fidelity of lighting interventions. Findings will establish evidence-based implementation strategies and the best design for SABL to reduce agitation for persons with ADRD in NHs.
Conditions Studied
Interventions
- OTHER Control
- DEVICE Smart Ambient Bright Light (SABL)
Study Locations (2)
Pennsylvania
- Valley View Retirement Community - Belleville
- Christ the King Manor - DuBois
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2023-12-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05825404
The ClinicalTrials.gov registry entry for NCT05825404 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,629-participant average among 5 other Alzheimer's Disease and Related Dementias trials with a reported enrollment target (97% lower). The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer's Disease and Related Dementias appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT05825404 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05825404 about?
NCT05825404 is a clinical study titled "Smart Lighting for Nursing Home Residents With Dementia". This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight. This SABL includes tunable LED lights, photosensors, and controllers. The SABL system has a pre-programmed 24-hour control ...
What is the current status of trial NCT05825404?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2023-04-24. Estimated completion is 2023-12-05.
What conditions does trial NCT05825404 study?
This clinical trial studies the following conditions: Alzheimer's Disease and Related Dementias.
What interventions are being tested in trial NCT05825404?
The interventions under investigation include: Control (OTHER), Smart Ambient Bright Light (SABL) (DEVICE).
Who is sponsoring clinical trial NCT05825404?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05825404 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer's Disease and Related Dementias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice
RECRUITING · NA
-
Translating Data Science to Palliative Care
COMPLETED · NA
-
Reducing Behavioral and Psychological Symptoms of Dementia: Hospital Caregivers (Aim 2)
COMPLETED · NA
-
OPTIMAL in NH Residents With Dementia
COMPLETED · NA
-
Preventing Alzheimer's With Cognitive Training
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.